NASDAQ:CELC Celcuity (CELC) Stock Price, News & Analysis $85.94 -2.40 (-2.72%) As of 10:40 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Celcuity Stock (NASDAQ:CELC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Celcuity alerts:Sign Up Key Stats Today's Range$85.30▼$89.5650-Day Range$87.32▼$142.5352-Week Range$13.59▼$151.02Volume140,887 shsAverage Volume1.12 million shsMarket Capitalization$4.19 billionP/E RatioN/ADividend YieldN/APrice Target$155.18Consensus RatingModerate Buy Company Overview Celcuity, Inc. is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors. Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways. These assays are intended to serve as companion diagnostics, guiding the use of therapies such as PARP inhibitors and other targeted molecules in oncology. In addition to its core diagnostic offerings, Celcuity collaborates with pharmaceutical companies to co-develop new companion tests alongside emerging drug candidates, aiming to streamline clinical development and regulatory approval. Headquartered in Malvern, Pennsylvania, Celcuity was founded in the mid-2000s by a team of scientists and clinicians with extensive experience in cancer biology and diagnostic innovation. The company’s operations are primarily focused on the North American market, where it provides testing services through its CAP-accredited and CLIA-registered laboratory. Celcuity’s leadership team brings together expertise in biopharma partnerships, clinical diagnostics, and regulatory affairs to advance its pipeline of precision oncology solutions. AI Generated. May Contain Errors. Read More Celcuity Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreCELC MarketRank™: Celcuity scored higher than 63% of companies evaluated by MarketBeat, and ranked 222nd out of 835 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingCelcuity has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on no strong buy ratings, 11 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialCelcuity has a consensus price target of $155.18, representing about 79.8% upside from its current price of $86.30.Amount of Analyst CoverageCelcuity has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Celcuity's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Celcuity are expected to grow in the coming year, from ($3.76) to $0.02 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Celcuity is -22.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Celcuity is -22.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCelcuity has a P/B Ratio of 39.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Celcuity's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted25.95% of the float of Celcuity has been sold short.Short Interest Ratio / Days to CoverCelcuity has a short interest ratio ("days to cover") of 8.56.Change versus previous monthShort interest in Celcuity has recently increased by 2.84%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCelcuity does not currently pay a dividend.Dividend GrowthCelcuity does not have a long track record of dividend growth. News and Social Media2.5 / 5News Sentiment-0.04 News SentimentCelcuity has a news sentiment score of -0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Celcuity this week, compared to 6 articles on an average week.Search Interest30 people have searched for CELC on MarketBeat in the last 30 days. This is an increase of 131% compared to the previous 30 days.MarketBeat Follows5 people have added Celcuity to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Company Ownership1.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Celcuity insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,781,140.00 in company stock.Percentage Held by Insiders13.33% of the stock of Celcuity is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions63.33% of the stock of Celcuity is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Celcuity's insider trading history. Receive CELC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Celcuity and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CELC Stock News HeadlinesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELCJuly 23 at 10:00 AM | prnewswire.comWith FDA approval, Celcuity sees big future for its new breast cancer drugJuly 22 at 7:04 PM | msn.comHave you seen Elon’s new “supercurrency”? (It affects you)Elon Musk just became the world's first trillionaire following the biggest IPO in history, giving him access to what millionaire trader Tim Bohen calls a rare supercurrency. Tim believes this shift could ripple into a handful of small, overlooked stocks in the coming weeks.July 24 at 1:00 AM | StocksToTrade (Ad)CELCUITY ALERT: Bragar Eagel & Squire, P.C. is Investigating Celcuity Inc. on Behalf of Celcuity Stockholders and Encourages Investors to Contact the FirmJuly 21 at 4:58 PM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELCJuly 21 at 1:26 PM | globenewswire.comCELC INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities FraudJuly 20, 2026 | globenewswire.comCelcuity (CELC) Receives a Buy from Leerink PartnersJuly 19, 2026 | theglobeandmail.comHC Wainwright Issues Negative Outlook for Celcuity EarningsJuly 19, 2026 | americanbankingnews.comSee More Headlines CELC Stock Analysis - Frequently Asked Questions How have CELC shares performed this year? Celcuity's stock was trading at $99.74 at the beginning of the year. Since then, CELC shares have decreased by 13.5% and is now trading at $86.2980. How were Celcuity's earnings last quarter? Celcuity, Inc. (NASDAQ:CELC) announced its quarterly earnings results on Thursday, May, 14th. The company reported ($0.97) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.10. Read the conference call transcript. When did Celcuity IPO? Celcuity (CELC) raised $22 million in an initial public offering on Tuesday, September 19th 2017. The company issued 2,400,000 shares at $8.00-$10.00 per share. Craig-Hallum Capital Group served as the underwriter for the IPO. Who are Celcuity's major shareholders? Celcuity's top institutional shareholders include Assenagon Asset Management S.A. (0.39%), Hennion & Walsh Asset Management Inc. (0.21%), Tema ETFs LLC (0.08%) and Handelsbanken Fonder AB (0.02%). Insiders that own company stock include David Dalvey and Richard E Buller. View institutional ownership trends. How do I buy shares of Celcuity? Shares of CELC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Celcuity own? Based on aggregate information from My MarketBeat watchlists, some other companies that Celcuity investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Palo Alto Networks (PANW) and ServiceNow (NOW). Company Calendar Last Earnings5/14/2026Today7/24/2026Next Earnings (Estimated)8/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 For the last 9 days, CELC's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryHealthcare Current SymbolNASDAQ:CELC CIK1603454 Webwww.celcuity.com Phone(763) 392-0767FaxN/AEmployees40Year Founded2012Price Target and Rating Average Price Target for Celcuity$155.18 High Price Target$178.00 Low Price Target$110.00 Potential Upside/Downside+79.8%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($3.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$177.04 million Net MarginsN/A Pretax MarginN/A Return on Equity-244.61% Return on Assets-50.22% Debt Debt-to-Equity Ratio6.04 Current Ratio12.31 Quick Ratio12.31 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.17 per share Price / Book39.77Miscellaneous Outstanding Shares48,770,000Free Float42,265,000Market Cap$4.21 billion OptionableOptionable Beta0.16 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:CELC) was last updated on 7/24/2026 by MarketBeat.com Staff. From Our PartnersThe 38% Crash Warning Every Retirement Saver Needs to Read Right NowThe AI trade has pushed stocks to record highs, everyone feels good, and retirement accounts look great on pap...Golden Crest Metals | SponsoredTrump is positioned. Elon lights the fuse.Earlier this year, the Trump-backed World Liberty Trust applied for a federal banking charter. Now, new report...Crypto 101 Media | SponsoredA Wall Street Veteran's Weekly Options Strategy ExplainedA former Merrill Lynch and Vanguard advisor spent 25 years watching one weekly options play generate consisten...Base Camp Trading | SponsoredGoldman Sachs: 300 million jobs will disappearGoldman Sachs predicts 300 million jobs will disappear - and Elon Musk's 'Project Apex' AI supercomputer is ac...InvestorPlace | SponsoredElon's next move will be bigger than the IPO – and it could happen any day nowHedge fund legend Larry Benedict - who delivered a 279% return on cash in 2025 and went on a 20-year winning s...Brownstone Research | SponsoredHave you seen Elon’s new “supercurrency”? (It affects you)Elon Musk just became the world's first trillionaire following the biggest IPO in history, giving him access t...StocksToTrade | SponsoredTwo paths to universal income. One already exists today.Robert Kiyosaki, author of Rich Dad Poor Dad, says there are two paths to Universal Basic Income - wait for El...Freedom Financial | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celcuity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celcuity With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
